The Analysis of Coagulation Factors Market

doi:10.13523/j.cb.20170517

China Biotechnology

2017, Vol. 37

Issue (5): 133-139 DOI: 10.13523/j.cb.20170517

The Analysis of Coagulation Factors Market

LI Min¹, WU Ri-wei²

1. Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China;
2. Nanchang National High-Tech Industrial Development, Nanchang 330096, China

Download:

HTML

PDF(510KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Coagulation factor is a kind of special drugs, which is the treatment drug for hemophilia and has become an important part of blood products. There are more than 20 kinds of recombinant coagulation factor listed in the global market and the market sales are 7.854 billion dollars in 2015. The sales of recombinant coagulation factors of Baxalta ranked first in the world, reaching 2.84 billion dollars. The issued institution of coagulation factors in domestic is good. With the abolishment of the maximum retail price of blood products by National Development and Reform Commission, the prices of all kinds of products have different ranges of growth. Among them, the growth rate of human fibrinogen is the highest, reaching 189%. There is great potential for domestic coagulation factor market. But some factors hinder the development of the market, such as products supply shortage and lacking of R&D efforts and so on. Reforming of the industry management system, improving the technology of plasma separation, strengthening the research and development of recombinant products is necessary now.

Key words： Global coagulation factor market Domestic coagulation factor market Coagulation factor

Received: 04 November 2016 Published: 25 May 2017

ZTFLH:

Q81

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

LI Min, WU Ri-wei. The Analysis of Coagulation Factors Market. China Biotechnology, 2017, 37(5): 133-139.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20170517 OR https://manu60.magtech.com.cn/biotech/Y2017/V37/I5/133

[1] 血制品:潜在市场空间巨大. 招商证券, 2016, 19(7):48. Blood products:huge potential market space. China Merchants Securities, 2016, 19(7):48.
[2] 李陆, 阎嘉, 刘佳, 等. 凝血因子及血浆蛋白类制品的研究现状及发展前景. 现代生物医学进展, 2014, 14(18):3578-3580. Li L, Yan J, Liu J, et al. The research status and prospects of coagulation factors and plasma protein products. Progress in Modern Biomedicine, 2014, 14(18):3578-3580.
[3] Gao F. The viral safety and rational use of plasma derivative products. China Licensed Pharmacist, 2012, 9(9):37-41.
[4] Burnouf T. Recombinant plasma proteins. Vox Sang, 2011, 100(1):68-83.
[5] 王娅, 卢丽, 黄晓倩, 等. 国产血液制品生产供应现状及改善策略探讨. 中国输血杂志, 2016, 29(4):431-435. Wang Y, Lu L, Huang X Q, et al. Analysis and strategic suggestion on the situation and progress of plasma fractionation in China. Chinese Journal of Blood Transfusion, 2016, 29(4):431-435.
[6] 李敏. 中国血液制品行业分析. 中国生物工程杂志. 2016,36(9):119-125. Li M. The analysis of Chinese blood biologicals industry. China Biotechnology, 2016,36(9):119-125.
[7] 吕茂民, 王方, 赵雄, 等. 凝血因子与创伤止血. 军事医学, 2015, 39(3):211-215. Lu M M, Wang F, Zhao X, et al. Coagulation factor and traumatic hemostasis. Military Medical Science, 39(3):211-215.

[1]	WANG Hui-lin,ZHOU Kai-qiang,ZHU Hong-yu,WANG Li-jing,YANG Zhong-fan,XU Ming-bo,CAO Rong-yue. Research Progress of Human Coagulation Factor VII and the Recombinant Expression Systems[J]. China Biotechnology, 2021, 41(2/3): 129-137.

[2]	. Research on the Expression of Human Coagulation Factor IX in Tobacco[J]. China Biotechnology, 2006, 26(03): 11-16.

Viewed

Full text

Abstract

Cited

Shared

Discussed